SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitfarms Ltd. (Canada) engages in the business of mining cryptocurrency. The firm is also involved in the ownership and operation of server farms comprised of computers designed for the purpose of validating transactions on the Bitcoin blockchain. The company was founded by Emiliano Joel Grodzki and Nicolas Bonta in 2017 and is headquartered in Toronto, Canada.

Bitfarms Ltd.

Bitfarms ($BITF) is trending as discussions revolve around its strategic shift toward AI and high-performance computing, alongside a recently announced offering. The community is weighing the potential impact of this move, with some viewing it as a positive step for long-term growth, while others express concerns about potential dilution. Investors are actively debating the implications of the offering and the company's future prospects in the evolving landscape of AI and cryptocurrency.

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Praxis Precision Medicines Inc

Praxis Precision Medicines is trending due to positive topline results from Phase 3 trials of ulixacaltamide HCl for essential tremor, sparking significant pre-market gains and heavy trading volume. The community is focused on the high institutional ownership potentially leading to a short squeeze, with some speculating on price targets. This movement occurs within the context of the essential tremor treatment space, where there is a large unmet need for effective therapies.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending due to a lawsuit from Singapore's GIC alleging inflated revenue figures, sparking debate about its impact. The community is divided, with some viewing it as a buying opportunity amidst recycled headlines and others expressing concern. Discussions also include delivery numbers, battery swap technology, and the broader context of Chinese EV competition.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as digital video compact disc player, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

Taiwan Semiconductor is trending after reporting strong Q3 earnings, driven by surging AI chip demand, and raising its 2025 revenue growth outlook. Community members are discussing the company's impressive profit increase and potential for further gains, while also noting geopolitical risks. Some analysts are raising price targets, citing TSMC's key role in the AI boom and strong guidance.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is trending as analysts update their ratings, citing a clear path to growth and potential investor sentiment improvement, especially with the company's AI integrations. Community discussions revolve around potential revival of the AI software/enterprise trade and possible short-term trading opportunities. The stock also garnered attention following Salesforce and Google's deepened partnership with Gemini integration, further emphasizing the company's focus on AI.

SPDR Gold Trust - SPDR Gold Shares ETF

SPDR Gold Shares ETF

SPDR Gold Shares ETF ($GLD) is trending as gold prices reach record highs, sparking debate about a potential bubble. While some community members foresee a continued surge driven by economic uncertainty and central bank buying, others anticipate a sharp correction, citing overbought conditions. Discussions revolve around shorting opportunities versus long-term bullish sentiment amidst global economic concerns.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending as community members debate its valuation and potential for a short squeeze, with some citing insider selling as a cause for concern. Discussions include potential catalysts for movement, such as earnings and possible offerings, amid speculation about the future of quantum computing stocks. Bears and bulls continue to clash over the stock's direction and long-term potential.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is currently trending due to community discussions around potential price movements and reactions to market volatility. Some traders are anticipating a breakout while others foresee a further dip, contributing to the heightened interest. Broader market factors, including potential impacts from economic news and stablecoin regulation, are also being closely monitored by investors.

American Battery Technology Co. is a technology company, which engages in the development and marketing of lithium-ion batteries. Its projects include recycling plant, United States Advanced Battery Consortium (USABC), and Tonopah flats. The company was founded on October 6, 2011 and is headquartered in Reno, NV.

American Battery Technology Company

ABAT is trending due to the termination of a DOE grant for its lithium hydroxide project, leading to a significant price drop and high trading volume. While the company is appealing the decision and states the project will continue unchanged, the community is debating the impact of the lost funding and potential need for alternative financing. Some investors view the dip as a buying opportunity, citing the company's long-term potential and strategic importance in the domestic battery technology sector.

Microvast Holdings, Inc. is an advanced battery technology company. It engages in the business of designing, developing, and manufacturing battery components and systems primarily for electric commercial vehicles and utility-scale energy storage systems. The company was founded by Yang Wu on October 12, 2006 and is headquartered in Stafford, TX.

Microvast Holdings Inc

MVST is trending as investors discuss its valuation relative to peers and potential catalysts like earnings and expansion plans. Community members are pointing to potential short squeezes and institutional buying, while also debating the company's ties to China. Overall, the discussion revolves around whether the stock is undervalued and poised for further gains.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

All You Need to Know About Sionna Therapeutics, Inc. (SION) Rating Upgrade to Buy

Sionna Therapeutics, Inc. (SION) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Wall Street Analysts See a 66.51% Upside in Sionna Therapeutics, Inc. (SION): Can the Stock Really Move This High?

The mean of analysts' price targets for Sionna Therapeutics, Inc. (SION) points to a 66.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

The short squeeze in Sionna Therapeutics shares that followed a 45% post-earnings rally has cooled, with shorts rising to 23.7% of free float from 21.5% as the stock slipped about 10% last week.The biopharmaceutical firm, which is developing novel therapies for cystic fibrosis, drew conflicting sell-side views, according to The Fly, which compiled data on the short squeeze from Ortex.&nbsp;Raymond James initiated coverage with a ‘Strong Buy’ rating and $45 price target, saying Sionna has the best chance in the industry at breaking Vertex Pharmaceuticals’ stronghold in cystic fibrosis. RBC Capital Markets began at ‘Sector Perform’ with a $22 target, noting that existing treatments set a high bar and that Sionna’s next key data readouts in mid-2026 may not meaningfully de-risk the program.Sionna is advancing two first-in-class NBD1 stabilizers, SION-719 and SION-451. Both produced positive Phase 1 safety and pharmacokinetic results in June, exceeding target exposure levels.&nbsp;The company plans to start a Phase 2a proof-of-concept trial of SION-719 as an add-on to standard of care in the second half of 2025 and a Phase 1 trial of SION-451 in two proprietary dual combinations over the same period, with topline data from both expected in mid-2026.&nbsp;Preclinical findings presented in June showed that the stabilizers, when combined with complementary modulators, enabled full correction of F508del-CFTR in models.In second-quarter results released last month, Sionna reported a net loss of $18.1 million, or a loss of $0.41 per share, compared with a loss of $2.71 a year earlier, on higher R&amp;D expenses of $15.4 million.&nbsp;General and administrative expenses rose to $6.5 million from $3.1 million. The company ended June with $337.3 million in cash and equivalents, which it stated&nbsp;should be sufficient to fund operations&nbsp;through 2028.On Stocktwits, retail sentiment for Sionna was ‘bearish’ amid ‘normal’ message volume.<a href="https://stocktwits.com/symbol/SION">Sionna’s stock</a> has declined 4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Sionna’s stock (SION) has declined 4% so far in 2025. (Photo credit: Getty Images)

Sionna Short Squeeze Fades As Raymond James Backs Cystic Fibrosis Breakthrough, RBC Warns Treatments Set High Bar

The biopharmaceutical firm’s shorts climbed to 23.7% of free float last week as the stock slipped 10%.

Equity

Sionna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in researching, developing and commercializing novel medicines for cystic fibrosis. It is focused on advancing a robust pipeline of small molecules and complementary CFTR modulators designed to deliver transformative clinical outcomes and improve the quality of life for individuals living with cystic fibrosis. The company was founded by Greg Hurlbut and Mark Munson in August 2019 and is headquartered in Waltham, MA.

Sionna Therapeutics Inc.

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.48	--	--	N/A
Q2 '25	-$0.56	-$0.41	26.13%	BEAT
Q1 '25	-$0.45	-$0.62	-38.55%	MISSED
Q4 '24	--	-$3.38	--	N/A

SION
Sionna Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest SION News

SIONSionna Therapeutics Inc